title: [Feasibility of peripheral vein during FOLFOX/FOLFIRI chemotherapy through peripheral venous system].
abstract: FOLFOX/FOLFIRI chemotherapy is usually applied through central venous catheters because of possible occurrence of phlebitis during application of these regimen via peripheral vein. However, the exact frequency and degree of the problems at peripheral venous access site during FOLFOX/FOLFIRI chemotherapy via peripheral vein in the clinical setting has not been reported previously. We investigated the frequency of infusion failure and phlebitis in 43 patients with advanced or recurrent colorectal cancer who received FOLFOX4, mFOLFOX6 or FOLFIRI chemotherapy in our institution. After informed consent, FOLFOX/FOLFIRI chemotherapy was applied via peripheral vein in 29 cases; all courses (13.1+/-8.1 (Mean+/-SD)courses, 5-FU: 3,510+/-743 mg/body/course) were completed via peripheral vein in the 20 cases (70%). In the other 9 cases, the access site was converted to the central vein because of the problems of access site following completion of 5.9+/-2.0 courses via peripheral vein. Fifty eight times of phlebitis were recognized during total of 301 courses; severe phlebitis requiring medical treatment was not recognized in any case. Seventy seven times of the change of venous access site were required during total of 301 courses. These data would be essential for the exact informed consent for choosing the access site for FOLFOX/FOLFIRI chemotherapy.
authors.affiliation: Dept. of Surgery, Osaka General Medical Center.
authors.forename: Toru
authors.initials: T
authors.lastname: Kimura
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Iwase
authors.forename: Toyokazu
authors.initials: T
authors.lastname: Aono
authors.forename: Sumio
authors.initials: S
authors.lastname: Nakai
authors.forename: Makoto
authors.initials: M
authors.lastname: Fujii
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Nishikawa
authors.forename: Chu
authors.initials: C
authors.lastname: Matsuda
authors.forename: Kazunori
authors.initials: K
authors.lastname: Shimada
authors.forename: Masashi
authors.initials: M
authors.lastname: Hirota
authors.forename: Satoka
authors.initials: S
authors.lastname: Nasu
authors.forename: Daiki
authors.initials: D
authors.lastname: Wada
authors.forename: Jun-ichi
authors.initials: J
authors.lastname: Hasegawa
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Tanaka
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D005240:Feasibility Studies; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007275:Injections, Intravenous; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010689:Phlebitis / Q000139:chemically induced / Q000453:epidemiology; D013997:Time Factors; D014699:Venules / Q000187:drug effects
chemical_list: D009944:Organoplatinum Compounds; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin